ReviewAccounts of chemical research2023
Ligand Chemistry in Antitumor Theranostic Nanoparticles.
Review in Accounts of chemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.Materials today. Bio · 2026Review
- Synthesis and characterization of bifunctional nanoprobes for targeted photodynamic therapy in breast cancer treatment.Discover nano · 2026Article
- Targeted Removal of HCV E2 N2 N-Glycan Is Associated with Improved Immune Responses in Mice.Biomolecules · 2026Article
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
- Potential therapeutic applications of medical gases in cancer treatment.Medical gas research · 2025Review
- Article
- Exploring necroptosis: mechanistic analysis and antitumor potential of nanomaterials.Cell death discovery · 2025Review
- Controlling Protein Immobilization over Poly(3-hydroxybutyrate) Microparticles Using Substrate Binding Domain from PHA Depolymerase.Biomacromolecules · 2025Article
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy.Frontiers in immunology · 2025Review
- Revolutionizing rheumatoid arthritis therapy: harnessing cytomembrane biomimetic nanoparticles for novel treatment strategies.Drug delivery and translational research · 2025Review
- Nanoparticles Modulating the Immune Microenvironment in Breast Cancer Treatment.International journal of nanomedicine · 2025Review
- Applications of Diels-Alder Chemistry in Biomaterials and Drug Delivery.Macromolecular bioscience · 2024Review
- Strategies for intravesical drug delivery: From bladder physiological barriers and potential transport mechanisms.Acta pharmaceutica Sinica. B · 2024Review
- Advances in Atherosclerosis Theranostics Harnessing Iron Oxide-Based Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Collision of herbal medicine and nanotechnology: a bibliometric analysis of herbal nanoparticles from 2004 to 2023.Journal of nanobiotechnology · 2024Review
- Redox-Responsive Gold Nanoparticles Coated with Hyaluronic Acid and Folic Acid for Application in Targeting Anticancer Therapy.Molecules (Basel, Switzerland) · 2024Article
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- Harnessing nanotechnology for cancer treatment.Frontiers in bioengineering and biotechnology · 2024Review
- Advancing Breast Cancer Therapeutics: Targeted Gene Delivery Systems Unveiling the Potential of Estrogen Receptor-Targeting Ligands.Biomaterials research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Theranostic nanoparticles' potential in tumor treatment has been widely acknowledged thanks to their capability of integrating multifaceted functionalities into a single nanosystem. Theranostic nanoparticles are typically equipped with an inorganic core with exploitable physical properties for imaging and therapeutic functions, bioinert coatings for improved biocompatibility and immunological stealth, controlled drug-loading-release modules, and the ability to recognize specific cell type for uptake. Integrating multiple functionalities in a single nanosized construct require sophisticated molecular design and precise execution of assembly procedures. Underlying the multifunctionality of theranostic nanoparticles, ligand chemistry plays a decisive role in translating theoretical designs into fully functionalized theranostic nanoparticles. The ligand hierarchy in theranostic nanoparticles is usually threefold. As they serve to passivate the nanoparticle's surface, capping ligands form the first layer directly interfacing with the crystalline lattice of the inorganic core. The size and shape of nanoparticles are largely determined by the molecular property of capping ligands so that they have profound influences on the nanoparticles' surface chemistry and physical properties. Capping ligands are mostly chemically inert, which necessitates the presence of additional ligands for drug loading and tumor targeting. The second layer is commonly utilized for drug loading. Therapeutic drugs can either be covalently conjugated onto the capping layer or noncovalently loaded onto nanoparticles via drug-loading ligands. Drug-loading ligands need to be equally versatile in properties to accommodate the diversity of drugs. Biodegradable moieties are often incorporated into drug-loading ligands to enable smart drug release. With the aid of targeting ligands which usually stand the tallest on the nanoparticle surface to seek and bind to their corresponding receptors on the target, theranostic nanoparticles can preferentially accumulate at the tumor site to attain a higher precision and quantity for drug delivery. In this Account, the properties and utilities of representative capping ligands, drug-loading ligands, and targeting ligands are reviewed. Since these types of ligands are often assembled in close vicinity to each other, it is essential for them to be chemically compatible and able to function in tandem with each other. Relevant conjugation strategies and critical factors with a significant impact on ligands' performance on nanoparticles are discussed. Representative theranostic nanoparticles are presented to showcase how different types of ligands function synergistically from a single nanosystem. Finally, the technological outlook of evolving ligand chemistry on theranostic nanoparticles is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.